CEO Matthew Mills to Host One-on-One Meetings with Institutional Investors at Preeminent Investor Conference for Small-Cap Public Companies
LOS ANGELES, CA / ACCESSWIRE / May 24, 2023 / Med-X, Inc., a leading innovator of all-natural green scene solutions addressing the pest control, health and wellness markets, today announced that management will attend the 13th Annual LD Micro Invitational, a preeminent small-cap investor conference, on Tuesday, June 6, 2023 at the Luxe Sunset Boulevard Hotel in Los Angeles, California.
LD Micro is a preeminent investor conference series for small-cap public companies, providing a forum for management teams to meet with hundreds of institutional investors, family offices, research analysts and other industry participants. Med-X CEO Matthew Mills is scheduled to host one-on-one meetings with institutional investors throughout the conference.
Matthew Mills, Chief Executive Officer of Med-X, said: 'As we continue our rapid cadence of operational execution, attending premier investor conferences such as LD Micro will allow us to cultivate ties with a new network of institutional and public market investors. I look forward to a day of productive meetings and networking, helping to bolster our visibility within the capital markets.'
Registration is mandatory for conference participation. For more information or to schedule a meeting, please contact MZ Group at MXRX@mzgroup.us.
About Med-X, Inc.
Med-X, Inc. is a leading innovator of biological pest control solutions addressing both consumer and professional markets globally. Nature-Cide - the Company's flagship product line - is a safer, all-natural alternative to conventional chemical products, formulated to kill or repel a wide variety of pests. Med-X's comprehensive go-to-market strategy includes leveraging strategic partnerships alongside an integrated e-commerce, brick and mortar and on-site services presence in key markets. For more information, please visit our website at www.medx-rx.com.
Disclaimer and Forward-Looking Statements
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities. Any offers, solicitations or offers to buy, or any sale of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended (the 'Securities Act'). This announcement is being issued in accordance with Rule 135 of the Securities Act. This press release may contain forward-looking statements regarding projected business performance, operating results, financial condition, and other aspects of the company, expressed by such language as 'expected,' 'anticipated,' 'projected' and 'forecasted.' Please be advised that such statements are estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the company. Forward-looking statements may be based on management assumptions that prove to be wrong. The Company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the Company incurring operating losses and experiencing unexpected material adverse events.
Investor Relations Contact
SOURCE: Med-X, Inc.
View source version on accesswire.com: